With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer therapies, with the potential to be used to treat a variety of other disease indications. The success of such products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, with substantially lower risk of treatment related side effects.

To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this link

The USD 15 billion (by 2030) financial opportunity within this market has been analyzed across the following segments:

Type of Payload
• MMAE
• DM4
• Camptothecin
• DM1
• MMAF
• Others

Type of Linker
• VC
• Sulfo-SPDB
• SMCC
• VA
• Hydrazone
• Others

Target Indication
• Breast cancer
• Lymphoma
• Leukemia
• Urothelial cancer
• Lung cancer
• Ovarian cancer
• Others

Target Antigen
• CD30
• HER2
• CD22
• CD33
• Others

Technology Providers
• Seattle Genetics
• ImmunoGen
• StemCentRx
• Immunomedics
• Others

Key Geographical Regions
• North America
• Europe
• Asia Pacific

The Antibody Drug Conjugates Market (5th Edition), 2019-2030 report features the following companies, which we identified to be key players in this domain:
• Bristol Myers Squibb
• GlaxoSmithKline
• Incyte
• Novartis
• Trillium Therapeutics

Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4.Market Overview
5. Company and Drug Profiles
6. Key Therapeutic Areas
7. Key Opinion Leaders
8. Target Competitiveness Analysis
9. Partnerships and Collaborations
10. Funding and Investment Analysis
11. Patent Analysis
12. Academic Grants
13. Key Commercialization Strategies
14. Promotional Analysis
15. Combination Therapies
16. Novel Conjugation Technology Platforms
17. Assessment of Non-Clinical Data, First in Human Dosing
18. Cost Price Analysis
19. Case Study: Contract Manufacturing of ADC
20. Case Study: Companion Diagnostics for ADC Therapeutic
21. Market Forecast and Opportunity Analysis
22. Swot Analysis
23. Conclusion
24. Executive Insights
25. Appendix 1: Tabulated Data

For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]